Related Experiment Video
Updated: May 11, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience]
H-P Hartung1, J Haas, M Meergans
1Neurologische Klinik im UKD, Medizinische Fakultät, Heinrich-Heine Universität, Moorenstr. 5, 40225 Düsseldorf, Deutschland. hans-peter.hartung@uni-duesseldorf.de
Interferon-beta1b has treated relapsing-remitting multiple sclerosis (MS) for over 20 years, showing long-term efficacy and safety. Early treatment initiation significantly impacts disease course and patient outcomes in multiple sclerosis management.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Context:
- Interferon-beta1b, approved in 1993 (USA) and 1995 (Europe), revolutionized multiple sclerosis (MS) treatment.
- Its use expanded to active secondary progressive MS (1999) and clinically isolated syndrome (2006).
Purpose:
- To provide a comprehensive overview of over 20 years of clinical experience with interferon-beta in MS.
- To focus on long-term efficacy, safety, and the impact of early treatment initiation.
Summary:
- Discusses mechanisms of action, disease-modifying therapy indications, and neutralizing antibodies.
- Explores adherence, therapy frequency, combination treatments, and safety in pediatric and pregnant MS patients.
Impact:
- Highlights the profound impact of early interferon-beta initiation on multiple sclerosis management.
- Provides insights into optimizing long-term interferon-beta therapy for diverse MS patient populations.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Multiple Sclerosis l: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
